The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This project builds on our experience with the ASAP Study (McGill University Health Centre research ethics board: MP-37-2020-4911). The goal of this study is to better understand the experience of migrant people with Human Immunodeficiency Virus (HIV) of having their treatment switched to Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). In other words, the investigators want to evaluate how feasible and acceptable this switch is, and how participants will take B/F/TAF (fidelity) and remain on it. The investigators also want to know more about migrant people with HIV's experience of care; namely, how often they see their HIV specialist or other healthcare professionals, and their healthcare coverage (the type of insurance that they have).
Phase:
PHASE4
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre